ZF2001

ZF2001
Butiran vaksin
Penyakit sasaranSARS-CoV-2
JenisSubunit protein
Data klinikal
Nama dagangZIFIVAX
Kaedah
pemberian		Intraotot
Pengecam
DrugBank

ZF2001 dengan nama cap dagang ZIFIVAX, ialah sejenis vaksin COVID-19 subunit protein tambahan yang dikembangkan oleh Anhui Zhifei Longcom dengan kerjasama Institut Mikrobiologi di Akademi Sains China.[1][2] Pada Disember 2020, vaksin ini telah dijalankan ujian tahap III dengan 29,000 orang peserta di China, Ecuador, Malaysia, Pakistan dan Uzbekistan.[3][4]

ZF2001 menggunakan teknologi yang serupa dengan vaksin berasaskan protein lain dalam percubaan Tahap III daripada Novavax, Vector Institute dan Medicago.[5] Vaksin ini diberikan dalam tiga dos dalam jangka masa dua bulan.[6]

ZF2001 pertama kali diluluskan untuk digunakan di Uzbekistan dan kemudian China.[7][8] Kapasiti pengeluaran dijangka mencecah satu bilion dos setahun.[6] Keputusan ujian tahap II yang diterbitkan dalam The Lancet melalui penggunaan tiga dos menunjukkan kadar serokonversi antibodi peneutralan antara 92% hingga 97%.[9]

Rujukan

  1. ^ "Anhui Zhifei Longcom: RBD-Dimer – COVID19 Vaccine Tracker". covid19.trackvaccines.org. Dicapai pada 2020-12-27.
  2. ^ "COVID-19 Vaccine: ZIFIVAX by Anhui Zhifei Longcom Biopharma, Institute of Microbiology Chinese Academy of Sciences". covidvax.org (dalam bahasa Inggeris). Dicapai pada 2020-12-27.
  3. ^ "Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials". South China Morning Post (dalam bahasa Inggeris). 2020-11-20. Dicapai pada 2020-12-27.
  4. ^ Ying TP (2020-12-07). "MYEG to conduct phase 3 clinical trial for China's Covid-19 vaccine in Msia | New Straits Times". NST Online (dalam bahasa Inggeris). Dicapai pada 2020-12-27.
  5. ^ Zimmer C, Corum J, Wee SL (2020-06-10). "Coronavirus Vaccine Tracker". The New York Times (dalam bahasa Inggeris). ISSN 0362-4331. Dicapai pada 2020-12-27.
  6. ^ a b "China's production bottleneck 'could be eased with latest Covid-19 vaccine'". South China Morning Post (dalam bahasa Inggeris). 2021-03-17. Dicapai pada 2021-03-18.
  7. ^ Liu, Roxanne (2021-03-15). "China IMCAS's COVID-19 vaccine obtained emergency use approval in China". Reuters (dalam bahasa Inggeris). Dicapai pada 2021-03-15.
  8. ^ Mamatkulov, Mukhammadsharif (2021-03-01). "Uzbekistan approves Chinese-developed COVID-19 vaccine". Reuters (dalam bahasa Inggeris). Dicapai pada 2021-03-02.
  9. ^ Yang, Shilong; Li, Yan; Dai, Lianpan; Wang, Jianfeng; He, Peng; Li, Changgui; Fang, Xin; Wang, Chenfei; Zhao, Xiang; Huang, Enqi; Wu, Changwei (2021-03-24). "Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials". The Lancet Infectious Diseases (dalam bahasa Inggeris). 0. doi:10.1016/S1473-3099(21)00127-4. ISSN 1473-3099. PMC 7990482. PMID 33773111.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.